Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

Cal­i­for­nia-based Cy­to­ki­net­ics an­nounced that pos­i­tive re­sults from a Phase II tri­al of afi­camten showed pos­i­tive re­sults in pa­tients bat­tling hy­per­trophic car­diomy­opa­thy.

The third co­hort of the RED­WOOD-HCM tri­al showed sub­stan­tial re­duc­tions in the av­er­age left ven­tric­u­lar out­flow tract gra­di­ent in pa­tients whose back­ground in­clud­ed be­ing treat­ed with disopy­ra­mide and a be­ta-adren­er­gic block­er. Each pa­tient re­ceived up to three dos­es dai­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.